Related Experiment Video
Updated: Jan 22, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
KSRP modulates melanoma growth and efficacy of vemurafenib
Wenwen Liu1, Chu-Fang Chou2, Shanrun Liu3
1State Key Laboratory of Structured Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, China; University of Chinese Academy of Sciences, Beijing 100049, China; Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States of America.
Abstract:
The majority of melanomas carry an oncogenic BRAF mutation (BRAFV600E), which results in constitutive kinase activity driving melanoma proliferation. While inhibitors of BRAFV600E (BRAFi) effectively lead to rapid tumor shrinkage, most patients treated with BRAFi develop acquired resistance. Identification of factors as regulators of melanoma growth and as potential sources of resistance is thus crucial for the design of improved therapies to treat advanced melanoma with more durable responses. Here, we show that KH-type splicing regulatory protein (KSRP) is critical for proliferation of melanoma cells without and with acquired resistance to vemurafenib. Silencing KSRP reduces cell proliferation and augments the growth suppressive effects of vemurafenib. We identify killin (KLLN), a p53-regulated DNA replication inhibitor, as a downstream effector of growth inhibition by KSRP silencing and demonstrate that KSRP promotes decay of KLLN mRNA through an RNA-protein interaction. Using heterologous mRNA reporters, we show that a U-rich element within the 3' untranslated region of KLLN is responsible for KSRP-dependent mRNA decay. These findings implicate that KSRP is an important regulator of melanoma cell growth in part through controlling KLLN mRNA stability.
Insights
KH-type splicing regulatory protein (KSRP) drives melanoma cell proliferation and vemurafenib resistance. Silencing KSRP reduces melanoma growth by increasing killin (KLLN) mRNA decay, offering new therapeutic targets for advanced melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Most melanomas harbor BRAFV600E mutations, driving proliferation.
- BRAF inhibitors (BRAFi) induce tumor shrinkage but acquired resistance is common.
- Identifying melanoma growth regulators and resistance factors is key for better therapies.
Purpose of the Study:
- To investigate the role of KH-type splicing regulatory protein (KSRP) in melanoma proliferation.
- To determine KSRP's involvement in acquired resistance to BRAFi.
- To identify downstream effectors of KSRP in melanoma.
Main Methods:
- KSRP silencing in melanoma cell lines.
- Assessment of cell proliferation and response to vemurafenib.
- Analysis of killin (KLLN) mRNA levels and stability.
- RNA-protein interaction studies and mRNA reporter assays.
Main Results:
- KSRP is crucial for melanoma cell proliferation, both with and without vemurafenib resistance.
- KSRP silencing reduces proliferation and enhances vemurafenib's growth-suppressive effects.
- KSRP promotes KLLN mRNA decay via interaction with a U-rich element in the 3' UTR.
- KLLN, a p53-regulated DNA replication inhibitor, is a downstream effector of KSRP silencing.
Conclusions:
- KSRP is a critical regulator of melanoma cell growth.
- KSRP influences melanoma progression and BRAFi resistance partly by controlling KLLN mRNA stability.
- Targeting KSRP may offer a strategy for durable responses in advanced melanoma.
Related Concept Videos
Self-Efficacy
Population Growth
Meristems and Plant Growth
Dose-Response Relationship: Potency and Efficacy
Exponential Growth
Relationship Growth

